NeurAxis, Inc. (NRXS)
NYSEAMERICAN: NRXS · IEX Real-Time Price · USD
2.980
+0.120 (4.20%)
At close: Jul 19, 2024, 4:00 PM
3.050
+0.070 (2.35%)
After-hours: Jul 20, 2024, 12:57 PM EDT
Company Description
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome.
The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022.
The company was founded in 2011 and is headquartered in Carmel, Indiana.
NeurAxis, Inc.
| Country | United States |
| Founded | 2011 |
| IPO Date | Aug 9, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Brian Carrico |
Contact Details
Address: 11611 N. Meridian St, Suite 330 Carmel, Indiana 46032 United States | |
| Phone | (812) 689-0791 |
| Website | neuraxis.com |
Stock Details
| Ticker Symbol | NRXS |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001933567 |
| CUSIP Number | 64134X201 |
| ISIN Number | US64134X2018 |
| Employer ID | 45-5079684 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Brian Carrico | President, Chief Executive Officer and Director |
| Dr. Adrian Miranda | Senior Vice President of Science and Technology and Chief Medical Officer |
| Thomas Carrico | Chief Regulatory Officer and Director |
| Dr. Christopher Robin Brown D.D.S. | Founder, Director of Innovation and Director |
| Gary Peterson | Founder, Director of Design and Engineering and Director |
| Timothy Robert Henrichs | Chief Financial Officer |
| Dan Clarence | Chief Operating Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 5, 2024 | 8-K | Current Report |
| Jul 1, 2024 | ARS | Filing |
| Jul 1, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 1, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 21, 2024 | PRE 14A | Other preliminary proxy statements |
| May 28, 2024 | 8-K | Current Report |
| May 20, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Apr 16, 2024 | 10-K | Annual Report |
| Apr 16, 2024 | 8-K | Current Report |